^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cosibelimab (CK-301)

    i
    Other names: CK-301, TG-1501, CK 301
    Associations

    News

    Trials
    Company:
    Fortress, TG Therap
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    8ms
    Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=500, Recruiting, Checkpoint Therapeutics, Inc. | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    cosibelimab (CK-301)
    1year
    Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. (PubMed, Front Med (Lausanne))
    In recent years, the combination therapy of nivolumab plus ipilimumab has gained ground in studies for its survival and response rate benefits in patients with advanced melanoma...On the contrary, in advanced and metastatic BCC, successful therapeutic strategies, such as vismodegib and sonidegib, are based on the inhibition of aberrant activation of the Hedgehog signaling pathway...In patients with locally advanced or metastatic SCC, who are not candidates for surgery or radiotherapy, anti-PD1 agents such as cemiplimab, pembrolizumab, and cosibelimab (CK-301) have shown significant results in terms of response rate. PD-1/PD-L1 inhibitors, such as avelumab, have also been used in Merkel carcinoma, achieving responses in half of the patients with advanced disease...Two of the most promising molecules used in combination with immunotherapy are cavrotolimod (a Toll-like receptor 9 agonist) and a Toll-like receptor 7/8 agonist...Neoadjuvant treatment with cemiplimab in CSCCs and nivolumab in MCCs has shown promising results. Despite the successes of these new drugs, the new challenges ahead will be to select patients who will benefit from these treatments based on biomarkers and parameters of the tumor microenvironment.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL15 (Interleukin 15)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • Erivedge (vismodegib) • Odomzo (sonidegib) • cavrotolimod (AST-008) • cosibelimab (CK-301)
    over1year
    CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=25, Terminated, Checkpoint Therapeutics, Inc. | N=560 --> 25 | Trial completion date: Dec 2025 --> Dec 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Dec 2022; Regional political conflict
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
    over1year
    CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=560, Active, not recruiting, Checkpoint Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
    over2years
    CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=560, Recruiting, Checkpoint Therapeutics, Inc. | Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Dec 2021
    Enrollment open • Trial initiation date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
    over2years
    Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=500, Recruiting, Checkpoint Therapeutics, Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Nov 2021
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    cosibelimab (CK-301)
    over2years
    CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=560, Not yet recruiting, Checkpoint Therapeutics, Inc. | Initiation date: Jun 2021 --> Sep 2021
    Clinical • Trial initiation date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
    3years
    CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=560, Not yet recruiting, Checkpoint Therapeutics, Inc.
    Clinical • New P3 trial • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)